FASN and metabolic dysfunction-associated steatohepatitis: Antagonizing FASN or ACC not only reduces inflammation caused by a high-fat diet, but also blocks fibrosis by suppressing the activation of hepatic stellate cells, making FASN or ACC as potential targets for treating NASH (Wei et al., 2016; Bates et al., 2020).